
Gabriel Silver
With more than 20 years of experience in Phases I–III clinical trials, Gab is a highly accomplished clinical research professional with strong global expertise in trial design, operational strategy and end-to-end study execution. He holds a Bachelor of Nursing and a Master of Health Sciences (Health Administration). He has also spent almost two decades serving on executive committees, advisory boards and scientific councils at both national and international levels.
Gab’s background spans academia, CROs and clinical sites. His leadership includes feasibility, startup, regulatory and ethics submissions, project management, recruitment and retention, vendor management and process improvement. He is currently the Senior Therapeutic Strategy Manager at Novotech, where he is recognised for his strategic insight, operational excellence and commitment to advancing clinical research worldwide.
ArticleThe future of obesity drugs starts in preclinical discovery
Progress in preclinical models and biomarker science is improving early-stage obesity drug development. This article outlines the emerging targets and technologies behind this shift.


